JP2008521827A5 - - Google Patents

Download PDF

Info

Publication number
JP2008521827A5
JP2008521827A5 JP2007543584A JP2007543584A JP2008521827A5 JP 2008521827 A5 JP2008521827 A5 JP 2008521827A5 JP 2007543584 A JP2007543584 A JP 2007543584A JP 2007543584 A JP2007543584 A JP 2007543584A JP 2008521827 A5 JP2008521827 A5 JP 2008521827A5
Authority
JP
Japan
Prior art keywords
agonist
receptor modulator
ethyl
phenyl
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007543584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521827A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/043044 external-priority patent/WO2006058316A1/en
Publication of JP2008521827A publication Critical patent/JP2008521827A/ja
Publication of JP2008521827A5 publication Critical patent/JP2008521827A5/ja
Withdrawn legal-status Critical Current

Links

JP2007543584A 2004-11-29 2005-11-28 Ｓ１ｐ受容体アゴニストの投与レジメン Withdrawn JP2008521827A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63148304P 2004-11-29 2004-11-29
PCT/US2005/043044 WO2006058316A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012040574A Division JP2012107059A (ja) 2004-11-29 2012-02-27 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2013043351A Division JP2013129664A (ja) 2004-11-29 2013-03-05 Ｓ１ｐ受容体アゴニストの投与レジメン

Publications (2)

Publication Number Publication Date
JP2008521827A JP2008521827A (ja) 2008-06-26
JP2008521827A5 true JP2008521827A5 (enExample) 2009-02-05

Family

ID=36046868

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007543584A Withdrawn JP2008521827A (ja) 2004-11-29 2005-11-28 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2012040574A Withdrawn JP2012107059A (ja) 2004-11-29 2012-02-27 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2013043351A Withdrawn JP2013129664A (ja) 2004-11-29 2013-03-05 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2014266267A Pending JP2015061883A (ja) 2004-11-29 2014-12-26 Ｓ１ｐ受容体アゴニストの投与レジメン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012040574A Withdrawn JP2012107059A (ja) 2004-11-29 2012-02-27 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2013043351A Withdrawn JP2013129664A (ja) 2004-11-29 2013-03-05 Ｓ１ｐ受容体アゴニストの投与レジメン
JP2014266267A Pending JP2015061883A (ja) 2004-11-29 2014-12-26 Ｓ１ｐ受容体アゴニストの投与レジメン

Country Status (21)

Country Link
US (3) US20090275553A1 (enExample)
EP (3) EP1819326B1 (enExample)
JP (4) JP2008521827A (enExample)
KR (4) KR20130041385A (enExample)
CN (2) CN101068536B (enExample)
AU (1) AU2005309378B2 (enExample)
BR (1) BRPI0518674A2 (enExample)
CA (1) CA2589265A1 (enExample)
ES (1) ES2495690T3 (enExample)
IL (2) IL183134A0 (enExample)
MA (1) MA29034B1 (enExample)
MX (1) MX2007006373A (enExample)
NO (2) NO20072401L (enExample)
NZ (2) NZ554720A (enExample)
PL (1) PL1819326T3 (enExample)
PT (1) PT1819326E (enExample)
RU (2) RU2478384C2 (enExample)
SG (2) SG158096A1 (enExample)
TN (1) TNSN07209A1 (enExample)
WO (1) WO2006058316A1 (enExample)
ZA (1) ZA200703328B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007109207A (ru) 2004-08-13 2008-09-20 Прикис Фамэсьютикэлс, Инк. (US) Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом
CA2589265A1 (en) * 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
PL1926483T3 (pl) * 2005-09-09 2011-05-31 Novartis Ag Leczenie chorób autoimmunologicznych
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2008248648B2 (en) * 2007-05-04 2012-02-23 Novartis Ag Use of S1P receptor modulator
DK2278960T4 (da) 2008-03-17 2020-01-27 Actelion Pharmaceuticals Ltd Dosisregimen til en selektiv sip1 receptoragonist
NZ589412A (en) * 2008-05-20 2012-11-30 Kyorin Seiyaku Kk Use of a sphingosine-1-phosphate (S1P) agonist for maintance of induced remission of autoimmune or inflammatory diseases after inital treatment
AU2009273259B2 (en) * 2008-07-23 2013-05-02 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
WO2010020610A1 (en) * 2008-08-18 2010-02-25 Novartis Ag Compounds for the treatment of peripheral neuropathies
MX2011006610A (es) 2008-12-18 2011-06-30 Novartis Ag Nueva forma polimorfica de acido 1-(4-{l-[(e)-4-ciclohexil-3 -trifluorometil-benciloxi-imino]-etil)-2-etil-bencil)-azetidin-3 carboxilico.
ES2478842T3 (es) * 2008-12-18 2014-07-23 Novartis Ag Sal clorhidrato del ácido 1-(4-(1-((E)-4-ciclohexil-3-trifluorometil-benziloxiimino)-etil)-2-etil-benzil)-azetidina-3-carboxílico
KR20160064245A (ko) * 2008-12-18 2016-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
AR074826A1 (es) * 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p
CA2747992C (en) * 2008-12-22 2017-11-07 Novartis Ag Dosage regimen of an s1p receptor agonist
AU2015275246B2 (en) * 2008-12-22 2018-02-01 Novartis Ag Dosage regimen for a S1P receptor agonist
AU2010300919A1 (en) 2009-09-29 2012-03-22 Novartis Ag Dosage regimen of an S1P receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
CA2794607A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives
PH12013501442B1 (en) 2011-01-07 2018-04-20 Novartis Ag Immunosuppressant formulations
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
HRP20200883T1 (hr) 2012-08-17 2020-09-04 Actelion Pharmaceuticals Ltd. Postupak za pripremanje (2z,5z)-5-(3-kloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međuproizvodi koji se koriste u navedenom postupku
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
JP6401257B2 (ja) 2013-10-11 2018-10-10 テイコク ファーマ ユーエスエー インコーポレーテッド 局所用スフィンゴシン−１−リン酸受容体アゴニスト製剤及びその使用方法
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
EA036075B1 (ru) 2014-12-11 2020-09-23 Актелион Фармасьютиклз Лтд Схема дозирования для селективного агониста рецептора s1p1
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US10250466B2 (en) * 2016-03-29 2019-04-02 Juniper Networks, Inc. Application signature generation and distribution
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008943A1 (fr) * 1992-10-21 1994-04-28 Yoshitomi Pharmaceutical Industries, Ltd. Compose 2-amino-1,3-propanediol et immunosuppresseur
ATE211726T1 (de) 1994-08-22 2002-01-15 Welfide Corp Benzolderivate und deren medizinische verwendung
HU224814B1 (en) * 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
USRE39072E1 (en) 1997-04-04 2006-04-18 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
EP1300405B1 (en) 2000-07-13 2007-04-18 Sankyo Company, Limited Amino alcohol derivatives
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
MXPA03008755A (es) 2001-03-26 2004-02-18 Novartis Ag Derivados de 2-amino-propanol.
WO2002080902A1 (en) * 2001-04-02 2002-10-17 Astrazeneca Ab Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
EP1383532B1 (en) * 2001-04-02 2011-05-04 Genentech, Inc. Combination therapy
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
JP4476623B2 (ja) * 2001-06-08 2010-06-09 ノバルティス アーゲー インスリン産生細胞移植片拒絶の処置または予防
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
BR0314760A (pt) * 2002-09-24 2005-07-26 Novartis Ag Compostos orgânicos
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2005000833A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
CA2589265A1 (en) * 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas

Similar Documents

Publication Publication Date Title
JP2008521827A5 (enExample)
RU2007124327A (ru) Курс лечения с использованием агониста рецептора s1p
US6436938B1 (en) Combination treatment for depression
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
RU2008108887A (ru) Жидкие составы
JP2004512328A5 (enExample)
JP2007507494A5 (enExample)
WO2006119958A2 (en) Use of flibanserin in the treatment of chronic pain
JP2019517587A5 (enExample)
JP2014505017A5 (enExample)
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
RU2008146816A (ru) Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
RU2009144846A (ru) Использование модулятора рецептора s1p
JP2004509857A5 (enExample)
JP2017512211A5 (enExample)
JP5941258B2 (ja) 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール
US20020165217A1 (en) Combination treatment for anxiety and depression
JP2007537287A5 (enExample)
RU2008108175A (ru) Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы
RU2010147881A (ru) ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА
US20020147206A1 (en) Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
RU2009138028A (ru) Новое профилактическое и/или лекарственное средство против невропатической боли
JP2005511571A5 (enExample)
WO2014008379A2 (en) Diamine and meglumine salt forms of fatty acids
RU2009138032A (ru) Новое профилактическое и/или лекарственное средство против диабетической невропатии